key: cord-0827096-xx5ws9ks
authors: Chowdhury, Trinath; Baindara, Piyush; Mandal, Santi M.
title: LPD-12, a Promising Lipopeptide to Control COVID-19
date: 2020-11-06
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106218
sha: c80036780bd9616b0ea72e54877fd19ede582001
doc_id: 827096
cord_uid: xx5ws9ks

The recent pandemic outbreak of SARS-CoV-2 associated with lethal atypical pneumonia COVID-19 is an urgent public health issue with an increasing rate of mortality and morbidity. Currently, there are no vaccines or therapeutics available for COVID-19 that demands an urgent search for a new drug to combat the pandemic of COVID-19. Lipid membrane alternation efficiency of small antimicrobial lipopeptides makes them able to block the viral membrane fusion to the host cell. Lipopeptides could serve as potential antiviral agents by interacting or competing with viral fusion proteins. Here, we screened seven different lipopeptides (tsushimycin, daptomycin, surfactin, bacillomycin, iturin, srfTE, LPD-12) and docked individually against spike (S)-glycoprotein of SARS-CoV-2. Based on the maximum docked score and minimum atomic contact energy, LPD-12 (-1137.38 kcal) is chosen appropriate molecule for proper binding with the S glycoprotein of SARS-CoV-2 and thus significantly interrupt its affinity of binding with angiotensin-converting enzyme-2 (ACE2), the only receptor molecule facilitates in disease development. Results confirm a strong binding affinity of LPD-12 with ACE2 with a binding free energy of -1621.62 kcal which can also prevent the binding of S-protein, reciprocally. Thus it can be concluded that LPD-12 may act as a potential therapeutic drug by reducing the entry of SARS-CoV-2 to the human cells via ACE2 receptor and related infections.

 Based on the maximum docked score and minimum atomic contact energy, LPD-12 is the best one for binding with the S glycoprotein which significantly interrupt its affinity of binding with angiotensin-converting enzyme-2 (ACE2), the only receptor molecule facilitates in disease development.

 Results confirm a strong binding affinity of LPD-12 with ACE2 with a binding free energy of -1621.62 kcal which can also prevent the binding of S-protein, reciprocally.

 Lipopeptides could serve as potential antiviral agents against SARS-CoV-2 by interacting or competing with viral fusion proteins. Lipid membrane alternation efficiency of small antimicrobial lipopeptides makes them able to block the viral membrane fusion to the host cell.

A previously unknown and potentially lethal coronavirus SARS-CoV-2 was reported in December 2019 in Wuhan, Hubei province of China [1] . SARS-CoV-2 is associate with an ongoing outbreak of lethal atypical pneumonia named COVID-19 and suggested possible origin from bat [2] . SARS-CoV-2 infections are now pandemic and declared a public health emergency of international concern by the World Health Organization. MERS-CoV, SARS-CoV and SARS-CoV-2 are the three highly pathogenic zoonotic coronaviruses that all belong to β-coronavirus [3] . Apart from highly pathogenic zoonotic pathogens, MERS-CoV, SARS-CoV, and SARS-CoV-2 that causes severe disease in humans, four low pathogenic coronaviruses are endemic in humans, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E that causes disease with mild symptoms [3] . To date there are no antivirals, vaccines or therapeutic strategies approved against any of the seven human infecting coronaviruses. All of the coronaviruses caused pandemics were finally controlled conventional control measures only like travel restrictions,patient's isolation and strategic social distancing.

The first instance during the viral infection is mediated by a homo-trimers form of trans-membrane spike (S) glycoprotein in the surface of SARS-CoV-2 [4] . Coronaviruses use distinct binding receptors of the host cell that recognized by specific domains present in the S1 subunit of different viral species. SARS-CoV and SARS-CoV-2, binds to angiotensinconverting enzyme 2 (ACE2) and enter target host cell using S B domain of S1 subunit of S glycoprotein [5] . Therefore, coronavirus entry into the susceptible host cells is a complex process involving specific receptor binding and host protease-mediated proteolytic cleavage of S-glycoprotein.

Conventional antiviral drugs have been designed to target viral proteins and host cell elements that are involved in the infection process. However, the first step of viral infection needed the involvement of lipid membranes of both virus and host cell that are conserved in nature. Small antimicrobial peptides have been reported to disrupt cell membranes of various pathogens including bacteria, fungi and cancer cells [6] . Surfactins are cyclic lipopeptides naturally produced by various strains of Bacillus subtilis and reported to have a broad spectrum of bioactivities [7] . Surfactin showed antiviral activity against several enveloped viruses such as herpes-simplex-virus (HSV-1, HSV-2), Vesicular stomatitis virus (VSV), Simian immunodeficiency virus (SIV), Newcastle disease virus (NDV) and Porcine epidemic diarrhea virus (PEDV) [8] [9] [10] . The antiviral activity of surfactin is due to the inhibition of membrane fusion events between the virus and host cell [11] . Entry of Influenza A viruses (IAV) is shown to restrict by inhibition of membrane fusion event by blocking or interacting with the HA2 subunit of hemagglutinin [12] . In another study, coiled-coil interaction of MERS-CoV and IAVs spike proteins to host cell membranes are confirmed to inhibit by short α-helical lipopeptides, thus providing the potential of lipopeptides to be used as broadspectrum antiviral agents. In the focus of same concern, in the present study, we suggested small lipopeptides as a potential tool to combat SARS-CoV-2 infections. 

With the attention of lipopeptides potential to inhibit viral membrane fusion with host , we screened available crystal structures of potential lipopeptides for interaction study Interestingly, we found a few potentially interacting lipopeptides with strong binding affinity to SARS-CoV-2 spike(S)-glycoprotein (Table 1) . These lipopeptides may serve as potential drugs to combat COVID-19 pandemic, however further in-vitro and in-vivo validation required. Further, these results provide a relatively broad scope for development of lipopeptide based drug development to treat COVID-19 and related viral diseases. The docking results of all tested lipopeptides and their interaction residues along with bond distances are described details in figure S1 and table S1.

The in-silico analysis of seven numbers of mostly abundant lipopeptides with Sprotein of SARS-CoV-2 revealed that LDP-12 (Lipopeptide detergent-12) is the best one among them ( Table 1 ). The interaction between LPD-12 and S-protein was higher than Sprotein with its receptor ACE2. The binding free energy was calculated as -1137.38 kcal which is best among all the tested lipopeptides and significantly higher than -866.21 kcal of S-protein and ACE2 complex ( Table 1 ). The binding free energy of LPD-12 and S-protein interaction is -1137.38 kcal which is It suggests that LDP-12 have more affinity to bind with S-protein. Again a similar type of docking was performed with angiotensin-converting enzyme-2 (ACE2) to see how strongly it binds with LPD-12 and helps in hindering the entry of virus within the body ( Figure S2 ). In-silico docking of ACE2 with LPD-12 clearly depicted strong binding energy of -1621.62 kcal.

LPD-12 and ACE2 complex again interacted with S-protein of SARS-CoV-2 ( Figure   1 ). The binding free energy of the SARS-CoV-2 complex with ACE2-LPD12 complex was calculated as -755.66 kcal. In this docking, the binding free energy between LPD12-ACE2 complexes with SARS-CoV-2 was reduced dramatically due to the strong binding affinity of LPD-12 with ACE2. ACE2 always has a prone to binding with S protein. As LPD-12 comes into play in-between the two molecules, the affinity of binding of ACE2 was much reduced.

The bond distance was also calculated between the SARS-CoV-2 with ACE2; SARS-CoV-2 with LPD-12; LPD-12 with ACE2 showing maximum binding affinity between two different atoms present in each chain (Table S1 ). In S-protein of SARS-CoV-2 and ACE2 docking, it was clearly seen that the bond distance between C:ILE 1097 of S-protein and A:ASP 615 of ACE2 was measured as 6.645 Å, whereas in S-protein-LPD12-ACE2 docking the similar bond distance was increased 108.690 Å which concludes that the binding site has been changed where LPD-12 comes into play. Similarly in SARS-CoV-2 and LPD12 docking, the bond distance between B:PRO 547 of SARS-CoV-2 and H:ALA 25 of LPD-12 was measured as 3.387 Å which is same in SARS-CoV-2/LPD12/ACE2 complexdocking. This data signifies the docking position of S-protein with LPD-12 remains unchanged. Again in LPD12-ACE2 docking, the bond distance was again measured between L:TYR 12 of LPD-12 and A:ASP 615 of ACE2 as 5.555Å which is similar in SARS-CoV-2-LPD12-ACE2 docking also. This highlight there is no change in the bonding position of ACE2 and LPD-12 whereas change occurred for S-protein and ACE2 complex. Moreover, the complex formation between S-protein and ACE2 has been reduced significantly in the presence of LPD-12.

S-glycoprotein contains two functional subunits S1 and S2, which are responsible for binding to the host cell receptor and fusion of the viral and host cell membrane, respectively [5] . The S-glycoprotein is cleaved by host proteases at the interface of S1/S2 subunits which remained non-covalently bound in the prefusion conformation before infection [13] . The distal S1-subunit with receptor-binding domain(s), plays a role in stabilization of the prefusion conformation of membrane-anchored S2-subunit that has fusion machinery [5] . Further, proteolytic cleavage at S2' site (located immediately upstream to the fusion peptide in S2 domain) within S2 subunit is needed for the fusion of viral and host cell membranes that includes extensive irreversible conformational changes [13] .Lipopeptides are well known for their antimicrobial activity with the mechanism of membrane disruption [7, 14, 15] . Lipopeptide detergents (LPDs) are class of amphiphiles which designed for the structural study of the integral membrane proteins [16] . LPDs are designed to α-helices which may self-assemble into cylindrical micelles to provide a closely mimicking environment of acyl chain packing like lipid bilayers.LPD-12 is good enough to mimic the lipid bilayer width. LPD-12 monomers adopt lipid bilayer conformation successfully and associated into cylindrical octamers [17] . LPD-12 proved as a very well behaving lipopeptide detergent with sequence acetyl-A(O12)AEAAEKAAKYAAEAAEKAAKA(O12)A-amide, where O12 refers as modified ornithine residues. LPD-12 designed to have a high propensity of α-helices formation that might interact with integral membrane lipids more efficiently and disintegrate the membrane lipid.

Interestingly, in a recent study, it has been shown that α-helical lipopeptides target viral membrane fusion proteins efficiently, suggested as a potentially broad-spectrum antiviral therapy. By considering the fact, LPD-12 as a docking ligand against SARS-CoV-2 S-protein and found strong binding efficiency. LPD-12 alters the binding of S-protein with ACE2 and reduces their affinity by blocking the target site. Our results suggest LPD-12 may be used as a potential therapeutic agent to treat COVID-19, however, experimental validation is further needed. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

The Proximal Origin of SARS-CoV-2. Virological

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Designing antimicrobial peptides: Form follows function

Lipopeptides in microbial infection control : Scope and reality for industry

Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis

Antiviral activity of antimicrobial lipopeptide from Bacillus subtilis fmbj against Pseudorabies Virus, Porcine Parvovirus, Newcastle Disease Virus and Infectious Bursal Disease Virus in vitro

Synthetic surfactin analogues have improved anti-PEDV properties

Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses

Super short membrane-active lipopeptides inhibiting the entry of influenza A virus

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Purification, biochemical characterization and self-assembled structure of a fengycin-like antifungal peptide from bacillus thuringiensis strain SM

Isolation and characterization of diverse antimicrobial lipopeptides produced by Citrobacter and Enterobacter

Lipopeptide detergents designed for the structural study of membrane proteins

Crystal structure of a self-assembling lipopeptide detergent at 1.20 Å